FOLD PE Ratio & Valuation, Is FOLD Overvalued

Historical Valuation

Amicus Therapeutics Inc (FOLD) is now in the Fair zone, suggesting that its current forward PS ratio of 6.13 is considered Fairly compared with the five-year average of 5.80. The fair price of Amicus Therapeutics Inc (FOLD) is between 10.22 to 17.34 according to relative valuation method.

Relative Value

Fair Zone

10.22-17.34

Current Price：14.37

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Amicus Therapeutics Inc (FOLD) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Amicus Therapeutics Inc (FOLD) has a current Price-to-Book (P/B) ratio of 19.11. Compared to its 3-year average P/B ratio of 21.04, the current P/B ratio is approximately -9.22% higher. Relative to its 5-year average P/B ratio of 18.31, the current P/B ratio is about 4.37% higher. Amicus Therapeutics Inc (FOLD) has a Forward Free Cash Flow (FCF) yield of approximately 0.22%. Compared to its 3-year average FCF yield of -2.18%, the current FCF yield is approximately -110.09% lower. Relative to its 5-year average FCF yield of -4.09%, the current FCF yield is about -105.38% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for FOLD competitors is 2.55, providing a benchmark for relative valuation. Amicus Therapeutics Inc Corp (FOLD.O) exhibits a P/S ratio of 6.13, which is 140.53% above the industry average. Given its robust revenue growth of 23.72%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of FOLD increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of FOLD in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is FOLD currently overvalued or undervalued?

What is Amicus Therapeutics Inc (FOLD) fair value?

FOLD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Amicus Therapeutics Inc (FOLD) is between 10.22 to 17.34 according to relative valuation method.

How does FOLD's valuation metrics compare to the industry average?

The average P/S ratio for FOLD's competitors is 2.55, providing a benchmark for relative valuation. Amicus Therapeutics Inc Corp (FOLD) exhibits a P/S ratio of 6.13, which is 140.53% above the industry average. Given its robust revenue growth of 23.72%, this premium appears sustainable.

What is the current P/B ratio for Amicus Therapeutics Inc (FOLD) as of Mar 12 2026?

As of Mar 12 2026, Amicus Therapeutics Inc (FOLD) has a P/B ratio of 19.11. This indicates that the market values FOLD at 19.11 times its book value.

What is the current FCF Yield for Amicus Therapeutics Inc (FOLD) as of Mar 12 2026?

As of Mar 12 2026, Amicus Therapeutics Inc (FOLD) has a FCF Yield of 0.22%. This means that for every dollar of Amicus Therapeutics Inc's market capitalization, the company generates 0.22 cents in free cash flow.

What is the current Forward P/E ratio for Amicus Therapeutics Inc (FOLD) as of Mar 12 2026?

As of Mar 12 2026, Amicus Therapeutics Inc (FOLD) has a Forward P/E ratio of 59.81. This means the market is willing to pay $59.81 for every dollar of Amicus Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Amicus Therapeutics Inc (FOLD) as of Mar 12 2026?

As of Mar 12 2026, Amicus Therapeutics Inc (FOLD) has a Forward P/S ratio of 6.13. This means the market is valuing FOLD at $6.13 for every dollar of expected revenue over the next 12 months.

FOLD Valuation